FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3102920585> ?p ?o ?g. }

• W3102920585 endingPage "2292" @default.
• W3102920585 startingPage "2292" @default.
• W3102920585 abstract "<h3>Importance</h3> Coronavirus disease 2019 (COVID-19) may lead to serious illness as a result of an excessive immune response. Fluvoxamine may prevent clinical deterioration by stimulating the σ-1 receptor, which regulates cytokine production. <h3>Objective</h3> To determine whether fluvoxamine, given during mild COVID-19 illness, prevents clinical deterioration and decreases the severity of disease. <h3>Design, Setting, and Participants</h3> Double-blind, randomized, fully remote (contactless) clinical trial of fluvoxamine vs placebo. Participants were community-living, nonhospitalized adults with confirmed severe acute respiratory syndrome coronavirus 2 infection, with COVID-19 symptom onset within 7 days and oxygen saturation of 92% or greater. One hundred fifty-two participants were enrolled from the St Louis metropolitan area (Missouri and Illinois) from April 10, 2020, to August 5, 2020. The final date of follow-up was September 19, 2020. <h3>Interventions</h3> Participants were randomly assigned to receive 100 mg of fluvoxamine (n = 80) or placebo (n = 72) 3 times daily for 15 days. <h3>Main Outcomes and Measures</h3> The primary outcome was clinical deterioration within 15 days of randomization defined by meeting both criteria of (1) shortness of breath or hospitalization for shortness of breath or pneumonia and (2) oxygen saturation less than 92% on room air or need for supplemental oxygen to achieve oxygen saturation of 92% or greater. <h3>Results</h3> Of 152 patients who were randomized (mean [SD] age, 46 [13] years; 109 [72%] women), 115 (76%) completed the trial. Clinical deterioration occurred in 0 of 80 patients in the fluvoxamine group and in 6 of 72 patients in the placebo group (absolute difference, 8.7% [95% CI, 1.8%-16.4%] from survival analysis; log-rank<i>P</i> = .009). The fluvoxamine group had 1 serious adverse event and 11 other adverse events, whereas the placebo group had 6 serious adverse events and 12 other adverse events. <h3>Conclusions and Relevance</h3> In this preliminary study of adult outpatients with symptomatic COVID-19, patients treated with fluvoxamine, compared with placebo, had a lower likelihood of clinical deterioration over 15 days. However, the study is limited by a small sample size and short follow-up duration, and determination of clinical efficacy would require larger randomized trials with more definitive outcome measures. <h3>Trial Registration</h3> ClinicalTrials.gov Identifier:NCT04342663" @default.
• W3102920585 created "2020-11-23" @default.
• W3102920585 creator A5028817447 @default.
• W3102920585 creator A5031780095 @default.
• W3102920585 creator A5032404657 @default.
• W3102920585 creator A5036689303 @default.
• W3102920585 creator A5039685475 @default.
• W3102920585 creator A5053095971 @default.
• W3102920585 creator A5068518210 @default.
• W3102920585 creator A5070687796 @default.
• W3102920585 creator A5077358847 @default.
• W3102920585 creator A5077659125 @default.
• W3102920585 creator A5081481500 @default.
• W3102920585 date "2020-12-08" @default.
• W3102920585 modified "2023-10-10" @default.
• W3102920585 title "Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19" @default.
• W3102920585 cites W1987804903 @default.
• W3102920585 cites W1988104979 @default.
• W3102920585 cites W1996799348 @default.
• W3102920585 cites W2000941955 @default.
• W3102920585 cites W2015411250 @default.
• W3102920585 cites W2023580320 @default.
• W3102920585 cites W2091828873 @default.
• W3102920585 cites W2113902650 @default.
• W3102920585 cites W2137760779 @default.
• W3102920585 cites W2162840262 @default.
• W3102920585 cites W2325525149 @default.
• W3102920585 cites W2914443670 @default.
• W3102920585 cites W2922499927 @default.
• W3102920585 cites W2931245270 @default.
• W3102920585 cites W2942615395 @default.
• W3102920585 cites W3001118548 @default.
• W3102920585 cites W3008827533 @default.
• W3102920585 cites W3009500736 @default.
• W3102920585 cites W3012310845 @default.
• W3102920585 cites W3012421327 @default.
• W3102920585 cites W3012721715 @default.
• W3102920585 cites W3013653866 @default.
• W3102920585 cites W3037701834 @default.
• W3102920585 cites W3041319886 @default.
• W3102920585 cites W3047449463 @default.
• W3102920585 cites W3048230590 @default.
• W3102920585 cites W3082201689 @default.
• W3102920585 cites W3082355253 @default.
• W3102920585 cites W4229485323 @default.
• W3102920585 cites W4292528167 @default.
• W3102920585 doi "https://doi.org/10.1001/jama.2020.22760" @default.
• W3102920585 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7662481" @default.
• W3102920585 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33180097" @default.
• W3102920585 hasPublicationYear "2020" @default.
• W3102920585 type Work @default.
• W3102920585 sameAs 3102920585 @default.
• W3102920585 citedByCount "386" @default.
• W3102920585 countsByYear W31029205852020 @default.
• W3102920585 countsByYear W31029205852021 @default.
• W3102920585 countsByYear W31029205852022 @default.
• W3102920585 countsByYear W31029205852023 @default.
• W3102920585 crossrefType "journal-article" @default.
• W3102920585 hasAuthorship W3102920585A5028817447 @default.
• W3102920585 hasAuthorship W3102920585A5031780095 @default.
• W3102920585 hasAuthorship W3102920585A5032404657 @default.
• W3102920585 hasAuthorship W3102920585A5036689303 @default.
• W3102920585 hasAuthorship W3102920585A5039685475 @default.
• W3102920585 hasAuthorship W3102920585A5053095971 @default.
• W3102920585 hasAuthorship W3102920585A5068518210 @default.
• W3102920585 hasAuthorship W3102920585A5070687796 @default.
• W3102920585 hasAuthorship W3102920585A5077358847 @default.
• W3102920585 hasAuthorship W3102920585A5077659125 @default.
• W3102920585 hasAuthorship W3102920585A5081481500 @default.
• W3102920585 hasBestOaLocation W31029205851 @default.
• W3102920585 hasConcept C126322002 @default.
• W3102920585 hasConcept C142724271 @default.
• W3102920585 hasConcept C168563851 @default.
• W3102920585 hasConcept C170493617 @default.
• W3102920585 hasConcept C204243189 @default.
• W3102920585 hasConcept C204787440 @default.
• W3102920585 hasConcept C27081682 @default.
• W3102920585 hasConcept C2775864247 @default.
• W3102920585 hasConcept C2776134451 @default.
• W3102920585 hasConcept C2777014857 @default.
• W3102920585 hasConcept C2779910183 @default.
• W3102920585 hasConcept C535046627 @default.
• W3102920585 hasConcept C71924100 @default.
• W3102920585 hasConceptScore W3102920585C126322002 @default.
• W3102920585 hasConceptScore W3102920585C142724271 @default.
• W3102920585 hasConceptScore W3102920585C168563851 @default.
• W3102920585 hasConceptScore W3102920585C170493617 @default.
• W3102920585 hasConceptScore W3102920585C204243189 @default.
• W3102920585 hasConceptScore W3102920585C204787440 @default.
• W3102920585 hasConceptScore W3102920585C27081682 @default.
• W3102920585 hasConceptScore W3102920585C2775864247 @default.
• W3102920585 hasConceptScore W3102920585C2776134451 @default.
• W3102920585 hasConceptScore W3102920585C2777014857 @default.
• W3102920585 hasConceptScore W3102920585C2779910183 @default.
• W3102920585 hasConceptScore W3102920585C535046627 @default.
• W3102920585 hasConceptScore W3102920585C71924100 @default.
• W3102920585 hasIssue "22" @default.
• W3102920585 hasLocation W31029205851 @default.

• next